文献速递消化道肿瘤与早癌肝病消化内镜

早期影像组学特征预测FOLFIRI联合贝伐珠单抗治疗结直肠癌肝转移患者预后

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
PubMed 文献 · Gut · 2019-05-17

本研究基于PRODIGE-9多中心前瞻性研究,在230例接受FOLFIRI联合贝伐珠单抗一线治疗的转移性结直肠癌患者中,利用基线和2个月CT构建影像组学特征(SPECTRA评分),并在训练组120例、验证组110例及外部验证组40例中验证。SPECTRA评分>0·02者总生存期较低,2个月SPECTRA评分预后价值与6个月RECIST评估相当,且优于RECIST1·1和形态学标准。

要点

  • SPECTRA评分在训练组、验证组和外部验证组中均与总生存期相关。
  • 2个月SPECTRA评分预后价值与6个月RECIST评估相同。
  • 2个月RECIST1·1非缓解与总生存期降低无关(验证组p=0·238)。

核心结论

  • 基线和2个月CT的影像组学特征(结合靶肝病灶总径减少、密度和计算纹理分析)能预测总生存期,并比RECIST1.1标准更好地识别良好缓解者。
  • 该工具需进一步前瞻性研究验证。

研究设计与样本

  • 本研究为PRODIGE-9多中心前瞻性研究的辅助研究,分析了491例接受FOLFIRI联合贝伐珠单抗治疗的转移性结直肠癌患者。
  • 在230例患者中,对优势肝病灶在基线和化疗后2个月进行计算机纹理分析,RECIST1·1评估在6个月进行。
  • 影像组学特征(SPECTRA评分)在120例患者中通过多变量Cox分析构建并锁定,在110例患者中验证,并在PRODIGE 20试验的另一队列40例患者中进行外部验证。

主要发现

  • 在训练队列中,总生存期的显著预测特征为:靶肝病灶总径减少(aHR=13·7,p=1·93×10-7)、峰度(ssf=4)降低(aHR=1·08,p=0·001)和优势肝病灶高基线密度(aHR=0·98,p<0·001)。
  • SPECTRA评分>0·02的患者在训练队列(p<0·0001)、验证队列(p<0·0008)和外部验证队列(p=0·0027)中总生存期较低。
  • 2个月SPECTRA评分的预后价值与6个月RECIST评估相同,而2个月时根据RECIST1·1的非缓解与验证队列中总生存期降低无关(p=0·238)。
  • 形态学缓解与总生存期无关(p=0·41)。

关键数值与推荐

  • SPECTRA评分截断值为>0·02,用于定义总生存期较低的患者组。
  • 训练队列中靶肝病灶总径减少的aHR=13·7(p=1·93×10-7),峰度(ssf=4)降低的aHR=1·08(p=0·001),优势肝病灶高基线密度的aHR=0·98(p<0·001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出该工具需进一步前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to build and validate a radiomic signature to predict early a poor outcome using baseline and 2-month evaluation CT and to compare it to the RECIST1·1 and morphological criteria defined by changes in homogeneity and borders. METHODS: This study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed. In 230 patients, computed texture analysis was performed on the dominant liver lesion (DLL) at baseline and 2 months after chemotherapy. RECIST1·1 evaluation was performed at 6 months. A radiomic signature (Survival PrEdiction in patients treated by FOLFIRI and bevacizumab for mCRC using contrast-enhanced CT TextuRe Analysis (SPECTRA) Score) combining the significant predictive features was built using multivariable Cox analysis in 120 patients, then locked, and validated in 110 patients. Overall survival (OS) was estimated with the Kaplan-Meier method and compared between groups with the logrank test. An external validation was performed in another cohort of 40 patients from the PRODIGE 20 Trial. RESULTS: In the training cohort, the significant predictive features for OS were: decrease in sum of the target liver lesions (STL), (adjusted hasard-ratio(aHR)=13·7, p=1·93×10-7), decrease in kurtosis (ssf=4) (aHR=1·08, p=0·001) and high baseline density of DLL, (aHR=0·98, p<0·001). Patients with a SPECTRA Score >0·02 had a lower OS in the training cohort (p<0·0001), in the validation cohort (p<0·0008) and in the external validation cohort (p=0·0027). SPECTRA Score at 2 months had the same prognostic value as RECIST at 6 months, while non-response according to RECIST1·1 at 2 months was not associated with a lower OS in the validation cohort (p=0·238). Morphological response was not associated with OS (p=0·41). CONCLUSION: A radiomic signature (combining decrease in STL, density and computed texture analysis of the DLL) at baseline and 2-month CT was able to predict OS, and identify good responders better than RECIST1.1 criteria in patients with mCRC treated by FOLFIRI and bevacizumab as a first-line treatment. This tool should now be validated by further prospective studies. TRIAL REGISTRATION: Clinicaltrial.gov identifier of the PRODIGE 9 study: NCT00952029.Clinicaltrial.gov identifier of the PRODIGE 20 study: NCT01900717.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Dohan A, Gallix B, Guiu B, et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut. 2019. PMID: 31101691. doi:10.1136/gutjnl-2018-316407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。